

Precertification update for Truvada (emtricitabine/tenofovir disoproxil fumarate) and Descovy (emtricitabine/tenofovir alafenamide)

This notice is to update the previous PrEP (pre-exposure prophylaxis) criteria that went into effect on January 6, 2020.

Effective immediately, precertification clinical criteria will change for the following medications when indicated for pre-exposure prophylaxis (PrEP):

- Truvada® (emtricitabine/tenofovir disoproxil fumarate)
- Descovy® (emtricitabine/tenofovir alafenamide)

When indicated for PrEP, Truvada and Descovy are subject to precertification. Requests for Truvada or Descovy may be approved when all the following criteria are met:

- Appropriate indication/population for PrEP:
 - Truvada: indicated for PrEP to reduce the risk of sexually acquired HIV-1 in adults at high risk¹
 - Descovy: indicated in at-risk adults and adolescents weighing at least 35 kg for PrEP to reduce the risk of HIV-1 infection from sexual acquisition, excluding individuals at risk from receptive vaginal sex²

This change applies to Amerigroup District of Columbia, Inc. enrollees enrolled in the District of Columbia Healthy Families Program, Alliance and the Immigrant Children's Program.

Our *Preferred Drug List* and searchable formulary are located on the provider website at <https://providers.amerigroup.com/DC> > Provider Resources & Documents > Pharmacy.

If you have questions about this communication, please contact your Provider Relations Representative or call Provider Services at 1-800-454-3730.

¹ Gilead Sciences, Inc. Truvada (emtricitabine/tenofovir disoproxil fumarate) package insert. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021752s047lbl.pdf. Revised March 2016. Accessed Nov. 18, 2019.

² Gilead Sciences, Inc. Descovy (emtricitabine/tenofovir alafenamide) package insert. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208215s000lbl.pdf. Revised April 2016. Accessed Nov. 18, 2019.